NICE no for Novartis' Lucentis is good news for Allergan's Ozurdex
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, is poised to decline Novartis' VEGF receptor agonist Lucentis (ranibizumab) for another indication, visual impairment caused by macular oedema secondary to central or branch retinal vein occlusion (C/BRVO). Allergan, which markets Ozurdex (dexamethasone implant), recommended by NICE for this indication earlier this year, will likely welcome the news.